A quantitative analysis of kinase inhibitor selectivity

被引:1963
作者
Karaman, Mazen W. [1 ]
Herrgard, Sanna [1 ]
Treiber, Daniel K. [1 ]
Gallant, Paul [1 ]
Atteridge, Corey E. [1 ]
Campbell, Brian T. [1 ]
Chan, Katrina W. [1 ]
Ciceri, Pietro [1 ]
Davis, Mindy I. [1 ]
Edeen, Philip T. [1 ]
Faraoni, Raffaella [1 ]
Floyd, Mark [1 ]
Hunt, Jeremy P. [1 ]
Lockhart, Daniel J. [1 ]
Milanov, Zdravko V. [1 ]
Morrison, Michael J. [1 ]
Pallares, Gabriel [1 ]
Patel, Hitesh K. [1 ]
Pritchard, Stephanie [1 ]
Wodicka, Lisa M. [1 ]
Zarrinkar, Patrick P. [1 ]
机构
[1] Ambit Biosci, San Diego, CA 92121 USA
关键词
D O I
10.1038/nbt1358
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets(1,2). The biological consequences of multi-kinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome(2-4). We present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome. The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns. To enable a global analysis of the results, we introduce the concept of a selectivity score as a general tool to quantify and differentiate the observed interaction patterns. We further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.
引用
收藏
页码:127 / 132
页数:6
相关论文
共 33 条
  • [1] Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer
    Allen, LF
    Lenehan, PF
    Eiseman, IA
    Elliott, WL
    Fry, DW
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (03) : 11 - 21
  • [2] Roscovitine targets, protein kinases and pyridoxal kinase
    Bach, S
    Knockaert, M
    Reinhardt, J
    Lozach, O
    Schmitt, S
    Baratte, B
    Koken, M
    Coburn, SP
    Tang, L
    Jiang, T
    Liang, DC
    Galons, H
    Dierick, JF
    Pinna, LA
    Meggio, F
    Totzke, F
    Schächtele, C
    Lerman, AS
    Carnero, A
    Wan, YQ
    Gray, N
    Meijer, L
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (35) : 31208 - 31219
  • [3] The specificities of protein kinase inhibitors: an update
    Bain, J
    McLauchlan, H
    Elliott, M
    Cohen, P
    [J]. BIOCHEMICAL JOURNAL, 2003, 371 : 199 - 204
  • [4] Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
    Bantscheff, Marcus
    Eberhard, Dirk
    Abraham, Yann
    Bastuck, Sonja
    Boesche, Markus
    Hobson, Scott
    Mathieson, Toby
    Perrin, Jessica
    Raida, Manfred
    Rau, Christina
    Reader, Valerie
    Sweetman, Gavain
    Bauer, Andreas
    Bouwmeester, Tewis
    Hopf, Carsten
    Kruse, Ulrich
    Neubauer, Gitte
    Ramsden, Nigel
    Rick, Jens
    Kuster, Bernhard
    Drewes, Gerard
    [J]. NATURE BIOTECHNOLOGY, 2007, 25 (09) : 1035 - 1044
  • [5] Targeting tyrosine kinases in cancer: The second wave
    Baselga, Jose
    [J]. SCIENCE, 2006, 312 (5777) : 1175 - 1178
  • [6] Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139
  • [7] Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
    Carter, TA
    Wodicka, LM
    Shah, NP
    Velasco, AM
    Fabian, MA
    Treiber, DK
    Milanov, ZV
    Atteridge, CE
    Biggs, WH
    Edeen, PT
    Floyd, M
    Ford, JM
    Grotzfeld, RM
    Herrgard, S
    Insko, DE
    Mehta, SA
    Patel, HK
    Pao, W
    Sawyers, CL
    Varmus, H
    Zarrinkar, PP
    Lockhart, DJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) : 11011 - 11016
  • [8] Molecular basis for specificity in the druggable kinome: sequence-based analysis
    Chen, Jianping
    Zhang, Xi
    Fernandez, Ariel
    [J]. BIOINFORMATICS, 2007, 23 (05) : 563 - 572
  • [9] SB-203580 IS A SPECIFIC INHIBITOR OF A MAP KINASE HOMOLOG WHICH IS STIMULATED BY CELLULAR STRESSES AND INTERLEUKIN-1
    CUENDA, A
    ROUSE, J
    DOZA, YN
    MEIER, R
    COHEN, P
    GALLAGHER, TF
    YOUNG, PR
    LEE, JC
    [J]. FEBS LETTERS, 1995, 364 (02) : 229 - 233
  • [10] Sorafenib in advanced clear-cell renal-cell carcinoma
    Escudier, Bernard
    Eisen, Tim
    Stadler, Walter M.
    Szczylik, Cezary
    Oudard, Stephane
    Siebels, Michael
    Negrier, Sylvie
    Chevreau, Christine
    Solska, Ewa
    Desai, Apurva A.
    Rolland, Frederic
    Demkow, Tomasz
    Hutson, Thomas E.
    Gore, Martin
    Freeman, Scott
    Schwartz, Brian
    Shan, Minghua
    Simantov, Ronit
    Bukowski, Ronald M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) : 125 - 134